Sunday 18 October 2026
Export BBOT’s income statement to Excel — free account
BridgeBio Oncology Therapeutics, Inc
BBOT Healthcare Biotechnology
In the quarter to June 2026, EPS fell 25.3% and free cash flow fell 88.8%, each against the same quarter a year earlier.
2.82
0.13
−4.41%
Follow BBOT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+4 more TTM periods Free account |
0.00% | 0.00% | 0.00% | (252.10%) | |
| (46.44%) | (59.79%) | (73.79%) | (96.69%) | ||
ROIC |
0.00% | 0.00% | (87.94%) | (127.66%) | |
Return on Tangible Assets |
(25.52%) | (33.65%) | (68.74%) | (95.04%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.01) | (3.68) | (1.63) | (1.89) | |
Free Cash Flow |
(87.24) | (114.50) | (130.68) | (151.56) | |
Capital Expenditures |
(0.54) | (0.61) | (0.47) | (0.28) | |
| Other line items | |||||
Cash ROIC |
(9.53%) | (13.69%) | (20.92%) | (27.62%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.77 | 0.85 | 0.85 | 0.83 | |
Depreciation/Fixed assets |
0.57 | 0.64 | 0.79 | 0.86 | |
Capex/Depreciation |
(1.16) | (0.99) | (0.63) | (0.38) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.99) | (3.66) | (1.63) | (1.89) | |
Capex per Share |
(0.01) | (0.02) | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates